Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 10/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4462108 | 0.88 | KDM4E (0.41) | P2RX7RIPK1KDM4ETAAR1KMT2A | |
| SCHEMBL4473064 | 0.78 | P2RX7 (0.67) | P2RX7 | |
| SCHEMBL4473069 | 0.78 | P2RX7 (0.44) | P2RX7 | |
| SCHEMBL4465053 | 0.71 | SMYD3 (0.38) | P2RX7RIPK1KMT2AMAPK1 | |
| SCHEMBL4474336 | 0.70 | KDM4E (0.44) | P2RX7KDM4ETAAR1KMT2ANPC1 | |
| SCHEMBL4480803 | 0.69 | P2RX7 (0.60) | P2RX7 | |
| SCHEMBL4462236 | 0.69 | P2RX7 (0.62) | P2RX7 | |
| SCHEMBL4462246 | 0.69 | P2RX7 (0.42) | P2RX7 | |
| SCHEMBL4465046 | 0.68 | P2RX7 (0.47) | P2RX7 | |
| SCHEMBL4480809 | 0.68 | P2RX7 (0.41) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1837330-B1 | Benzamide inhibitors of the P2X7 receptor | PFIZER PROD INC (US) | 2012-10-24 | — | — | EP | disclosed |
| US-7553972-B2 | Benzamide inhibitors of the P2X7 receptor | PFIZER, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| EP-1837330-A1 | Benzamide inhibitors of the P2X7 receptor | Pfizer Products Inc. (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070142329-A1 | Benzamide Inhibitors of the P2X7 Receptor | PFIZER INC. | 2007-06-21 | — | — | US | disclosed |
| US-7186742-B2 | Benzamide inhibitors of the P2X7 receptor | PFIZER INC (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1626962-B1 | BENZAMIDE INHIBITORS OF THE P2X7 RECEPTOR | PFIZER PROD INC (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1626962-A1 | BENZAMIDE INHIBITORS OF THE P2X7 RECEPTOR | Pfizer Products Inc. (US) | 2006-02-22 | — | — | EP | disclosed |
| US-20050009900-A1 | Benzamide inhibitors of the P2X7 receptor | ZOETIS LLC | 2005-01-13 | — | — | US | disclosed |
| WO-2004099146-A1 | BENZAMIDE INHIBITORS OF THE P2X7 RECEPTOR | PFIZER PRODUCTS INC. (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142329-A1 | Benzamide Inhibitors of the P2X7 Receptor | IL1R1, P2RY1, P2RX1 | P2RX7 7/4885RIPK1 1002/4885KDM4E 4185/4885 |
| US-20050009900-A1 | Benzamide inhibitors of the P2X7 receptor | IL1R1, P2RY1, P2RX1 | P2RX7 7/4885RIPK1 1002/4885KDM4E 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.